Filing Flows

Filing Flows › Calumet (CLMT) › Stock forecast & fair value

Calumet (CLMT) stock forecast and fair value

Calumet (CLMT) trades at $39.68. 5 analysts' median price target is $57.00 (+44%), from $40.00 to $75.00. Across 13 valuation methods the middle fair value is $24.22 (-39%); the DCF says $29.30.

Price$39.68
Median target$57.00
Fair value, middle$24.22
DCF$29.30
EPS beat rate100%
Calumet fair value by method (price $39.68)Calumet fair value by method (price $39.68)low – highpoint estimateRegime-switching Monte Carlo 10th–9…$22.24DCF — Monte Carlo 10th–90th percent…$29.30EV/Sales vs peers$17.08EV/Sales vs peers, weighted$21.37EV/Sales vs peers, matched$11.17Analysts' price targets$55.80Outside view — base-rate Monte Carlo$28.48EV/Sales vs Rule of 40 (all-company…$121.51Stage-weighted value (high growth)$44.04Combined forecast (3 months)$41.43

Fair value by method

MethodLowPointHighvs price
Regime-switching Monte Carlo 10th–90th−$160.31$22.24$246.22-44%
DCF — Monte Carlo 10th–90th percentile−$210.90$29.30$233.89-26%
EV/Sales vs peers$5.03$17.08$27.53-57%
EV/Sales vs peers, weighted$8.81$21.37$75.97-46%
EV/Sales vs peers, matched$4.43$11.17$60.41-72%
Analysts' price targets$40.00$55.80$75.00+41%
Outside view — base-rate Monte Carlo−$61.88$28.48$147.36-28%
EV/Sales vs Rule of 40 (all-company fit)$30.24$121.51$371.89+206%
Stage-weighted value (high growth)−$78.63$44.04$194.03+11%
Combined forecast (3 months)$32.66$41.43$51.29+4%

Calumet's latest quarter

Calumet, Q3 2026: revenue $1.7B (+56% year over year), operating margin 27.0%, net earnings $256M, operating cash flow $218M. The chart follows the revenue to costs, profit and cash.

Questions

What is the price target for CLMT stock?

The median of 5 analysts' 12-month targets is $57.00, +44% from $39.68; the range is $40.00 to $75.00. The average rating is buy.

What is Calumet's fair value?

The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $11.17 and $121.51, with a middle value of $24.22 against a price of $39.68. Each method's assumptions are on the page.

Does Calumet usually beat earnings estimates?

It beat the consensus EPS estimate in 100% of the quarters on record.

Is CLMT stock a buy?

Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.